Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 1/2 3Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Multiple Myeloma 133Recurrence 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasms, Plasma Cell 15Neoplasms 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia 7Immunoglobulin Light-chain Amyloidosis 7Lymphoma, Non-Hodgkin 6Amyloidosis 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Hematologic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Burkitt Lymphoma 5Paraproteinemias 4Lymphoma, Mantle-Cell 4Leukemia, Myeloid, Acute 4Hematologic Diseases 4Blood Protein Disorders 4Neoplasm Metastasis 3Myelodysplastic Syndromes 3Lymphoma, B-Cell 3Lung Neoplasms 3Esophageal Neoplasms 3Corneal Diseases 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2

Interventions

Cyclophosphamide 25Rituximab 22fludarabine 14Lenalidomide 10Vincristine 8Doxorubicin 8Prednisone 7Etoposide 7fludarabine phosphate 6Immunotherapy, Adoptive 5polatuzumab vedotin 4Cytarabine 4CT-P10 4Bendamustine Hydrochloride 4Antigens, CD19 4tocilizumab 3Gemcitabine 3Dexamethasone 3Carboplatin 3venetoclax 2veltuzumab 2prednylidene 2ofatumumab 2obinutuzumab 2ixazomib 2ibrutinib 2etoposide phosphate 2deltacortene 2carmustine, poliferprosan 20 drug combination 2acalabrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, B-Cell × Dexamethasone × Clear all
NCT03114865 2025-05-22

A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Active not recruiting
44 enrolled
LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04882163 2021-10-05

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Celgene

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, B-Cell

NCT02983097 2018-01-19

R²-DHAP

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Phase 1/2 Terminated
34 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡